Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as First Line Treatment for Chinese Patients With Unresectable Biliary Tract Cancers

NCT05924880 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05924880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05924880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as First Line Treatment for Chinese Patients With Unresectable Biliary Tract Cancers
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
July 21, 2023
Completion date
February 7, 2025
Enrollment
116 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancers